Regulatory News
Wednesday, May 25, 2016
BRIEF-Innocoll says Xaracoll meets primary endpoint in Phase 3 trials in postoperative pain relief
* Announces Xaracoll (Bupivacaine-Collagen bioresorbable
implant) meets primary endpoint in both pivotal phase 3 trials
in postoperative pain relief
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment